{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:17Z","timestamp":1793212037939,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 169195"],"award-info":[{"award-number":["PJT 169195"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.reprotox.2025.108939","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:16:22Z","timestamp":1746443782000},"page":"108939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Meta-analysis and systematic review on Sulfasalazine\/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-2111","authenticated-orcid":false,"given":"Rashi","family":"Asthana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Hamandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brnabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Papadimitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Piquette-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12887-015-0532-3","article-title":"Maternal and neonatal outcomes in pregnant women with autoimmune diseases in Pavia, Italy","volume":"15","author":"Mazzucchelli","year":"2015","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.reprotox.2025.108939_bib2","unstructured":"M. Carroll et al., Crohn\u2019s and Colitis Canada: Impact of Inflammatory Bowel Disease in Canada. Crohn\u2019s and Colitis Canada, 2018."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib3","first-page":"96","article-title":"Pregnancy and inflammatory bowel disease","volume":"11","author":"Hashash","year":"2015","journal-title":"Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00002018-199921040-00006","article-title":"Treating inflammatory bowel disease during pregnancy. Risks and safety of drug therapy","volume":"21","author":"Connell","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.reprotox.2025.108939_bib6","unstructured":"Pfizer, Azulfidine: Product Monograph, 2009."},{"key":"10.1016\/j.reprotox.2025.108939_bib7","unstructured":"Pfizer, Salazopyrin: Product Monograph, 2019."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.reprotox.2025.108939_bib9","unstructured":"Pfizer, Product Monograph: Salazopyrin, 2020."},{"issue":"8","key":"10.1016\/j.reprotox.2025.108939_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/gut.2005.078097","article-title":"Fertility and pregnancy in the patient with inflammatory bowel disease","volume":"55","author":"Mahadevan","year":"2006","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib11","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2018.07.011","article-title":"Effects of various pharmaceutical excipients on the intestinal transport and absorption of sulfasalazine, a typical substrate of breast cancer resistance protein transporter","volume":"107","author":"Sawangrat","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.reprotox.2025.108939_bib12","doi-asserted-by":"crossref","unstructured":"U. Klotz, Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid, 1985.","DOI":"10.2165\/00003088-198510040-00001"},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s40495-016-0076-8","article-title":"Challenges and opportunities with predicting in vivo phase II metabolism via glucuronidation from in vitro data","volume":"2","author":"Ge","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib14","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1128\/AAC.02414-14","article-title":"Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites","volume":"58","author":"Zhong","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s11095-008-9537-z","article-title":"BCRP\/ABCG2 in the placenta: Expression, function and regulation","volume":"25","author":"Mao","year":"2008","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cts.12742","article-title":"Role of elevated SFLT-1 on the regulation of placental transporters in women with pre-eclampsia","volume":"13","author":"Kojovic","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.intimp.2015.04.020","article-title":"Maternal bacterial infections impact expression of drug transporters in human placenta","volume":"26","author":"Petrovic","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1744666X.2016.1184973","article-title":"Treatment of rheumatoid arthritis during pregnancy: present and future","volume":"12","author":"F\u00f6rger","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14656566.2016.1197204","article-title":"Challenges and treatment options for rheumatoid arthritis during pregnancy","volume":"17","author":"Gerosa","year":"2016","journal-title":"Expert Opin. Pharm."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.reprotox.2025.108939_bib21","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions, ver. 6.4. ."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/nhs.12353","article-title":"Systematic reviews: guidelines, tools and checklists for authors","volume":"19","author":"Lockwood","year":"2017","journal-title":"Nurs. Health Sci."},{"key":"10.1016\/j.reprotox.2025.108939_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.reprotox.2025.108939_bib24","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology (MOOSE): A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.reprotox.2025.108939_bib25","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions, Chapter 10: Analysing data and undertaking meta-analyses. ."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib26","first-page":"211","article-title":"The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome","volume":"6","author":"Baiocco","year":"1984","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2013.09.061","article-title":"Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications","volume":"146","author":"Ban","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2036.2011.04794.x","article-title":"Pregnancy outcome in inflammatory bowel disease: Prospective European case-control ECCO-EpiCom study, 2003\u20132006","volume":"34","author":"Bortoli","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0129567","article-title":"Inflammatory bowel disease and risk of adverse pregnancy outcomes","volume":"10","author":"Boyd","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.reprotox.2025.108939_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0016-5085(98)70628-6","article-title":"The safety of mesalamine in human pregnancy: a prospective controlled cohort study","volume":"114","author":"Diav-Citrin","year":"1998","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.crohns.2012.08.012","article-title":"Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel","volume":"7","author":"Dotan","year":"2013","journal-title":"J. Crohn\u2019S. Colitis"},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/00365521.2013.879734","article-title":"Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring","volume":"49","author":"K\u00e4ll\u00e9n","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.25.1.52","article-title":"Crohn\u2019s disease and pregnancy","volume":"25","author":"Khosla","year":"1984","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib34","first-page":"1224","article-title":"The safety of corticosteroids and sulfasalazine in pregnancy associated with inflammatory bowel disease","volume":"78","author":"Mogadam","year":"1980","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3109\/00365528309182088","article-title":"Pregnancy in ulcerative colitis","volume":"18","author":"Nielsen","year":"1983","journal-title":"Scand. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1080\/00365521.1984.12005800","article-title":"Pregnancy in Crohn\u2019s disease","volume":"19","author":"Nielsen","year":"1984","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.52.2.243","article-title":"Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study","volume":"52","author":"N\u00f8rg\u00e5rd","year":"2003","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib38","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/j.1572-0241.2007.01355.x","article-title":"Disease activity in pregnant women with Crohn\u2019s disease and birth outcomes: a regional Danish cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.reprotox.2025.108939_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.21.6.469","article-title":"Ulcerative colitis and pregnancy","volume":"21","author":"Willoughby","year":"1980","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.17189","article-title":"The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study","volume":"56","author":"N\u00f8rg\u00e5rd","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0016-5085(81)90193-1","article-title":"Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome","volume":"80","author":"Mogadam","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.reprotox.2025.108939_bib42","unstructured":"Atnahs Pharma UK Limited, Product Monograph: Dipentum Olsalazine Sodium, 2015."},{"issue":"12","key":"10.1016\/j.reprotox.2025.108939_bib43","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/00365521.2016.1208269","article-title":"Preterm birth in women with inflammatory bowel disease \u2013 the association with disease activity and drug treatment","volume":"51","author":"Broms","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/MIB.0000000000001113","article-title":"Indications for mode of delivery in pregnant women with inflammatory bowel disease","volume":"23","author":"Burke","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"10.1016\/j.reprotox.2025.108939_bib45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/aje\/153.10.961","article-title":"Neural tube defects in relation to use of folic acid antagonists during pregnancy","volume":"153","author":"Hernandez-Diaz","year":"2001","journal-title":"Am. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib46","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izy081","article-title":"Pregnancy-onset inflammatory bowel disease: a subtle diagnosis","volume":"24","author":"Koslowsky","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.reprotox.2005.01.008","article-title":"Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists","volume":"20","author":"Meijer","year":"2005","journal-title":"Reprod. Toxicol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2036.2001.00962.x","article-title":"Population-based case control study of the safety of sulfasalazine use during pregnancy","volume":"15","author":"N\u00f8rg\u00e5rd","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib49","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1572-0241.2007.01216.x","article-title":"Therapeutic drug use in women with Crohn\u2019s disease and birth outcomes: a Danish nationwide cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib50","first-page":"2006","article-title":"Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study","volume":"98","author":"N\u00f8rg\u00e5rd","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.0004-8666.2003.00127.x","article-title":"Findings on potential teratogens from a case-control study in Western Australia","volume":"43","author":"Werler","year":"2003","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14767050410001668662","article-title":"Perinatal outcomes in inflammatory bowel disease","volume":"15","author":"Bush","year":"2004","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib53","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"De Man","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijgo.2005.06.003","article-title":"Inflammatory bowel disease and preterm delivery","volume":"90","author":"Elbaz","year":"2005","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0002-9378(89)90324-4","article-title":"Inflammatory bowel disease: a controlled study of late pregnancy outcome","volume":"160","author":"Fedorkow","year":"1989","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/jp.2014.41","article-title":"Association between maternal inflammatory bowel disease and adverse perinatal outcomes","volume":"34","author":"Getahun","year":"2014","journal-title":"J. Perinatol."},{"issue":"22","key":"10.1016\/j.reprotox.2025.108939_bib57","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200011303432204","article-title":"Folic acid antagonists during pregnancy and the risk of birth defects","volume":"343","author":"Hernandez-Diaz","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/00365521.2013.879200","article-title":"Influence of medical treatment, smoking and disease activity on pregnancy outcomes in Crohn\u2019s disease","volume":"49","author":"Julsgaard","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0091270010390806","article-title":"Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists","volume":"52","author":"Levy","year":"2012","journal-title":"J. Clin. Pharm."},{"issue":"16","key":"10.1016\/j.reprotox.2025.108939_bib60","first-page":"1","article-title":"Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case-control study based on national registers","volume":"18","author":"Lindstrom","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2125.2009.03544.x","article-title":"Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations","volume":"68","author":"Matok","year":"2009","journal-title":"Br. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib62","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3109\/14767058.2012.684176","article-title":"Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain","volume":"25","author":"Oron","year":"2012","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12664-015-0542-y","article-title":"Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy","volume":"34","author":"Puri","year":"2015","journal-title":"Indian J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0002-9378(51)90014-2","article-title":"Pregnancy in idiopathic ulcerative colitis","volume":"61","author":"Abramson","year":"1951","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib65","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1440-1746.2006.04754.x","article-title":"Pregnancy before and after the diagnosis of inflammatory bowel diseases: Retrospective case-control study","volume":"22","author":"Bortoli","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib66","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.cgh.2012.08.018","article-title":"Complications from inflammatory bowel disease during pregnancy and delivery","volume":"10","author":"Br\u00f6ms","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib67","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.39137","article-title":"Brief report: Miscarriages in female rheumatoid arthritis patients: associations with serologic findings, disease activity, and antirheumatic drug treatment","volume":"67","author":"Brouwer","year":"2015","journal-title":"Arthritis Rheuma"},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheuma"},{"issue":"9","key":"10.1016\/j.reprotox.2025.108939_bib69","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","article-title":"The effects of active IBD during pregnancy in the era of novel IBD therapies","volume":"111","author":"De Lima-Karagiannis","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/art.38281","article-title":"Does medication use or disease activity during pregnancy in patients with rheumatoid arthritis affect bone density in their prepubertal offspring?","volume":"66","author":"De Steenwinkel","year":"2014","journal-title":"Arthritis Rheuma"},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/art.38519","article-title":"Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring","volume":"66","author":"De Steenwinkel","year":"2014","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.reprotox.2025.108939_bib72","first-page":"603","article-title":"Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis\u2014results from a JIA biologic registry","volume":"59","author":"Drechsel","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib73","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10067-017-3939-4","article-title":"Pregnancy in rheumatoid arthritis: a retrospective study","volume":"37","author":"Eudy","year":"2018","journal-title":"Clin. Rheuma"},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib74","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MEG.0000000000001117","article-title":"Decision making and outcome of pregnancies in female patients with inflammatory bowel disease: findings from a community-based practice","volume":"30","author":"Hoekstra","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.reprotox.2025.108939_bib75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0020-7292(97)00088-X","article-title":"Fertility and pregnancy in inflammatory bowel disease","volume":"58","author":"Hudson","year":"1997","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2169\/internalmedicine.8550-16","article-title":"Relationship between the clinical course of ulcerative colitis during pregnancy and the outcomes of pregnancy: a retrospective evaluation","volume":"57","author":"Ito","year":"2018","journal-title":"Intern. Med."},{"issue":"10","key":"10.1016\/j.reprotox.2025.108939_bib77","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2015-207992","article-title":"Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study","volume":"75","author":"Jakobsson","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1597\/02-077","article-title":"Maternal drug use and infant cleft lip\/palate with special reference to corticoids","volume":"40","author":"K\u00e4ll\u00e9n","year":"2003","journal-title":"Cleft Palate Craniofac. J."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib79","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/acr.20422","article-title":"Patterns of medication use during pregnancy in rheumatoid arthritis","volume":"63","author":"Kuriya","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib80","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02603416","article-title":"Ulcerative colitis in pregnancy in Israel","volume":"24","author":"Levy","year":"1981","journal-title":"Dis. Colon Rectum"},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib81","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year TREAT Registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib82","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2007.07.019","article-title":"Pregnancy outcomes in women with inflammatory bowel disease: A large community-based study from Northern California","volume":"133","author":"Mahadevan","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/00365521.2013.772229","article-title":"Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey","volume":"48","author":"Manosa","year":"2013","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1572-0241.2000.01852.x","article-title":"Crohn\u2019s disease, pregnancy, and birth weight","volume":"95","author":"Moser","year":"2000","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib85","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2004.04140.x","article-title":"The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients","volume":"99","author":"Moskovitz","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.reprotox.2025.108939_bib86","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1007\/s10620-016-4353-5","article-title":"Long-term disease course and pregnancy outcomes in women with inflammatory bowel disease: an Indian cohort study","volume":"62","author":"Padhan","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"11","key":"10.1016\/j.reprotox.2025.108939_bib87","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/acr.21807","article-title":"Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia","volume":"64","author":"Palmsten","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib88","doi-asserted-by":"crossref","first-page":"376","DOI":"10.17772\/gp\/2426","article-title":"Perinatal outcome in women with inflammatory bowel disease","volume":"86","author":"Wozniak","year":"2015","journal-title":"Ginekol. Pol."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib89","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1572-0241.2007.01756.x","article-title":"Relapses of inflammatory bowel disease during pregnancy: In-hospital management and birth outcomes","volume":"103","author":"Reddy","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.reprotox.2025.108939_bib90","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/BF01347293","article-title":"Chronic idiopathic ulcerative colitis\u2014Pregnancy and fetal outcome","volume":"29","author":"Schade","year":"1984","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.reprotox.2025.108939_bib91","first-page":"314","article-title":"Effect of pregnancy on the disease activity in ulcerative colitis","volume":"25","author":"Siddiqui","year":"2011","journal-title":"J. Postgrad. Med. Inst."},{"key":"10.1016\/j.reprotox.2025.108939_bib92","doi-asserted-by":"crossref","unstructured":"H.J. Tumen and E.M. Cohn, \u201cPregnancy and chronic ulcerative colitis,\u201d 1950.","DOI":"10.1016\/S0016-5085(19)36588-6"},{"issue":"3","key":"10.1016\/j.reprotox.2025.108939_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand. J. Rheuma"},{"key":"10.1016\/j.reprotox.2025.108939_bib94","series-title":"Birth outcome in women with ulcerative colitis and Crohn\u2019s disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy: Thesis defense","author":"Norgard","year":"2011"},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib95","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reprod. Toxicol."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib96","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ecco-jcc\/jjz211","article-title":"Inflammatory bowel disease and risk of birth defects in offspring","volume":"14","author":"Auger","year":"2020","journal-title":"J. Crohn\u2019S. Colitis"},{"issue":"6","key":"10.1016\/j.reprotox.2025.108939_bib97","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.reprotox.2025.108939_bib98","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.112.197046","article-title":"Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats","volume":"343","author":"Huang","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.reprotox.2025.108939_bib99","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/00365528109182032","article-title":"Placental transfer of sulfasalazine and sulphapyridine and some of its metabolites","volume":"16","author":"J\u00e4rnerot","year":"1981","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.reprotox.2025.108939_bib100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/00365528109182032","article-title":"Placental transfer of sulfasalazine and sulphapyridine and some of its metabolites","volume":"16","author":"J\u00e4rnerot","year":"1981","journal-title":"Scand. J. Gastroenterol."},{"issue":"6204","key":"10.1016\/j.reprotox.2025.108939_bib101","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bmj.2.6204.1553","article-title":"Placental and mammary transfer of sulfasalazine","volume":"2","author":"Khan","year":"1979","journal-title":"Br. Med. J."},{"key":"10.1016\/j.reprotox.2025.108939_bib102","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/00016348709022049","article-title":"Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid","volume":"66","author":"Christensen","year":"1987","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"1","key":"10.1016\/j.reprotox.2025.108939_bib103","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.22374\/1710-6222.25.1.5","article-title":"Meta-analysis of pregnancy outcomes after exposure to TNF-\u03b1 inhibitors during pregnancy for the treatment of arthritic diseases","volume":"25","author":"Mirdamadi","year":"2018","journal-title":"J. Popul. Ther. Clin. Pharm."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623825001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623825001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:46:31Z","timestamp":1762314391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623825001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":103,"alternative-id":["S0890623825001108"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2025.108939","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis and systematic review on Sulfasalazine\/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2025.108939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108939"}}